Personal profile
Contact Info
Dr Orod Osanlou is a Senior Clinical Lecturer in Pharmacology/Pharmacy at Bangor University. Amongst his university roles, he is the medical school Therapeutics Lead, and the Lead for the Prescribing Safety Assessment. As a Consultant in Clinical Pharmacology and Therapeutics, and General Internal Medicine, Dr Osanlou also works clinically at Betsi Calwaladr University Health Board. He is also the Director of the North Wales Clinical Research Facility, where there are opportunities for junior doctors and medical students to undertake placements and get invovled in research.
External positions
Local Councillor, Wirral Council
1 Nov 2021 → …
Director, North Wales Clinical Research Facility
1 Oct 2021 → …
Lead Principal Investigator, Vaccine Trials, Public Health Wales
1 Aug 2020 → …
Consultant Physician, Clinical Pharmacology and Therapeutics, General Internal Medicine, Betsi Cadwaladr University Health Board
1 Feb 2020 → …
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Research output
- 7 Article
-
Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID ‐19: A Dose‐Escalating, Randomized Controlled Phase Ib Study
Rowland, T., FitzGerald, R., Challenger, E., Dickinson, L., Else, L. J., Walker, L., Hale, C., Shaw, V., Kelly, C., Lyon, R., Gibney, J., Dhamani, K., Irwin, M., Enever, Y., Tetlow, M., Wood, W., Reynolds, H., Chiong, J., Osanlou, O. & Pertinez, H. & 12 others, , 18 Mar 2026, (E-pub ahead of print) In: Clinical Pharmacology and Therapeutics.Research output: Contribution to journal › Article › peer-review
Open AccessFile2 Downloads (Pure) -
Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial
Heath, P. T., Galiza, E. P., Baxter, D. N., Boffito, M., Browne, D., Burns, F., Chadwick, D. R., Clark, R., Cosgrove, C. A., Galloway, J., Goodman, A. L., Heer, A., Higham, A., Iyengar, S., Jeanes, C., Kalra, P. A., Kyriakidou, C., Bradley, J. M., Munthali, C. & Minassian, A. M. & 25 others, , 1 Feb 2023, In: Clinical Infectious Diseases. 76, 3, p. 398-407 10 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile5 Downloads (Pure) -
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial
Liu, X., Munro, A. P. S., Feng, S., Janani, L., Aley, P. K., Babbage, G., Baxter, D., Bula, M., Cathie, K., Chatterjee, K., Dejnirattisai, W., Dodd, K., Enever, Y., Qureshi, E., Goodman, A. L., Harndahl, L., Haughney, J., Hicks, A., van der Klaauw, A. A. & Kwok, J. & 37 others, , Jun 2022, In: Journal of Infection. 84, 6, p. 795-813 19 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile61 Downloads (Pure) -
Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial
2019nCoV-302 Study Group, Feb 2022, In: Lancet Respiratory Medicine. 10, 2, p. 167-179Research output: Contribution to journal › Article › peer-review
-
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial
Munro, A. P. S., Feng, S., Janani, L., Cornelius, V., Aley, P. K., Babbage, G., Baxter, D., Bula, M., Cathie, K., Chatterjee, K., Dodd, K., Enever, Y., Qureshi, E., Goodman, A. L., Green, C. A., Harndahl, L., Haughney, J., Hicks, A., Klaauw, A. A. V. D. & Kanji, N. & 344 others, , 1 Aug 2022, In: Lancet Infectious Diseases. 22, 8, p. 1131-1141 11 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile83 Downloads (Pure)